Saltar al contenido

Moderna, Inc. (MRNA) stock: revenue, earnings & dividend

Moderna, Inc. (MRNA, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener MRNA · Nasdaq Pharma & Biotech US-MA

Key figures

Fiscal year
2025
Revenue
1.94 bn $
Revenue growth
-39.9 %
Revenue growth 5y (p.a.)
19.3 %
Net income
-2.82 bn $
Net margin
-145.2 %
Operating margin
-158.1 %
Earnings per share (diluted)
-7.26 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
12.3 bn $
Equity
8.65 bn $
Equity ratio
70.1 %
Return on equity
-32.6 %
Cash
2.6 bn $
Operating cash flow
-1.87 bn $
Free cash flow
-2.07 bn $
Shares outstanding
404,620,975

History

Revenue by fiscal year

2016 108 m $
2017 206 m $
2018 135 m $
2019 60.2 m $
2020 803 m $
2021 18.5 bn $
2022 19.3 bn $
2023 6.85 bn $
2024 3.24 bn $
2025 1.94 bn $

Net income by fiscal year

2016 -216.21 m $
2017 -255.92 m $
2018 -384.73 m $
2019 -514 m $
2020 -747 m $
2021 12.2 bn $
2022 8.36 bn $
2023 -4.71 bn $
2024 -3.56 bn $
2025 -2.82 bn $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20251.94 bn $-2.82 bn $-7.26 $–-1.87 bn $
20243.24 bn $-3.56 bn $-9.28 $–-3 bn $
20236.85 bn $-4.71 bn $-12.33 $–-3.12 bn $
202219.3 bn $8.36 bn $20.12 $–4.98 bn $
202118.5 bn $12.2 bn $28.29 $–13.6 bn $
2020803 m $-747 m $-1.96 $–2.03 bn $
201960.2 m $-514 m $-1.55 $–-459 m $
2018135 m $-384.73 m $––-330.87 m $
2017206 m $-255.92 m $––-331.48 m $
2016108 m $-216.21 m $––66.7 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)